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Summary
 Background Haematopoietic stem cell transplantation (HSCT) is a speciﬁ c therapeutic meth-
od used for biomodulation antitumour therapy of haematological malignancies 
and of solid tumours. It is also used for the therapy of non-tumour and heredi-
tary diseases.
 Aim To analyse the selected psychosocial, health and demographic aspects of quality 
of life (QoL) in acute myeloid leukaemia (AML) and multiple myeloma (MM) 
survivors undergoing autologous progenitor stem cell transplantation (PSCT).
 Materials/Methods The total number of AML survivors was 12 (7 male, 5 female). The total number 
of MM survivors was 32 (18 male, 14 female). The average age of AML survivors 
was 47.5 years old. Average age of MM survivors was 60 years old. The Czech ver-
sion of the international generic European Quality of Life Questionnaire, Version 
EQ-5D, was used. The effect of selected psychosocial, health and demographic 
aspects of QoL was determined by means of analysis of variance. The descriptive 
analysis was used for evaluation of QoL questionnaires.
 Results The above-mentioned aspects proved statistically signiﬁ cant dependence of QoL 
(EQ-5D score and EQ-5D VAS) on age in both cohorts (p<0.01), religion in AML 
cohort (p<0.05), smoking abuse in both cohorts (p<0.01), level of education in 
AML cohort (p<0.05), increasing number of associated diseases in both cohorts 
(p<0.05) and type of disease (p<0.05). Global QoL in AML survivors is at a much 
higher level than in MM survivors undergoing autologous PSCT.
 Conclusions Low QoL correlates with increasing age of survivors treated with autologous 
PSCT. QoL in survivors who underwent autologous PSCT and believed in God 
was higher than in survivors who were non-believers. Low QoL correlates with 
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BACKGROUND
QoL is deﬁ ned as “a patient’s subjective evalu-
ation of his life situation” [1,2]. The QoL term 
contains the information of an individual’s phys-
ical, psychological, social and spiritual condition 
[1–4]. QoL evaluation is carried out by means of 
generic and speciﬁ c questionnaires. Generic QoL 
questionnaires generally evaluate a patient’s over-
all condition regardless of his disease. Speciﬁ c 
QoL questionnaires are designed for the evalu-
ation of a patient’s overall condition in a partic-
ular type of disease. Modules are often used with 
these speciﬁ c questionnaires. These modules are 
focused on speciﬁ c symptoms and complaints in 
a particular type of disease [1–4].
Haematopoietic stem cell transplantation (HSCT) 
is a speciﬁ c therapeutic method used for bio-
modulation antitumour therapy of haematolog-
ical malignancies and of solid tumours. It is also 
used for therapy of non-tumour and hereditary 
diseases [5]. It is divided into: bone marrow trans-
plantation (BMT), transplantation of stem (pro-
genitor) cells (PSCT), and umbilical cord blood 
transplantation (UCBT) [5–7]. From a donor’s 
point of view there are three kinds of HSCT: syn-
genic transplantation (the donor is a monozygotic 
twin), allogeneic HSCT (HLA from a compatible 
sibling or parent or HLA from a compatible do-
nor), autologous HSCT (the patient himself is the 
donor). The aim of HSCT is to replace a patient’s 
pathological bone marrow which contains tumor-
ous cells with haematopoietic cells from a healthy 
donor and to restore hematopoiesis which is dam-
aged by intensive antitumour therapy [5–7].
The aim of the current QoL study was to analyse 
the effects of selected psychosocial, health and 
demographic aspects on QoL in acute myeloid 
leukaemia (AML) and multiple myeloma (MM) 
survivors undergoing autologous PSCT and to 
evaluate global QoL in AML and MM survivors 
undergoing autologous PSCT.
Design of Study
The study is cross-sectional and retrospective 
and it is based on data obtained during the year 
2004/2005 (from September 1, 2004 to January 
31, 2005) in 12 AML survivors and 32 MM sur-
vivors undergoing autologous PSCT between 
2001 and 2003 at the Department of Clinical 
Haematology of the 2nd Internal Clinic of Charles 
University Hospital and Faculty of Medicine in 
Hradec Kralove, Czech Republic.
Study Population
The total number of AML survivors undergoing 
autologous PSCT was 12 (7 male, 5 female). The 
average age of AML survivors was 47.5 years old 
(range 27–68 years old). The total number of MM 
survivors undergoing autologous PSCT was 32 (18 
male, 14 female). The average age of MM survi-
vors was 60 years old (range 45–78 years old).
QoL Questionnaire
The Czech version of the international generic 
EuroQol EQ-5D Questionnaire was used in the 
study [1]. This questionnaire evaluates 2 indi-
cators, objective and subjective indicators. The 
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smoking abuse. In both cohorts of survivors we proved lower QoL in smokers in 
comparison with non-smokers or former smokers. Low QoL in AML survivors 
with low level of education, meaning survivors with elementary and apprentice 
level education, has been proved. Low QoL correlates with increasing number 
of associated diseases in both cohorts of survivors.
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objective indicator includes 5 dimensions of QoL: 
mobility, self-care, usual activities, pain/discom-
fort, anxiety / depression [1,8,9]. Three kinds of 
answers which express the degree of complaints 
are offered to each question (no complaints, mild 
complaints, severe complaints). In total there are 
243 (35) combinations of health condition. The 
outcome is the EQ-5D score (dimensions of QoL), 
which has values from 0 to 1 (0 – the worst health 
condition, 1 – the best health condition). The 
subjective indicator uses a visual analogous scale 
(value of 100 – the best health condition, value 
of 0 – the worst health condition). The respond-
ent marks his subjectively perceived health con-
dition on the thermometer scale. The outcome is 
EQ-5D VAS (subjective health condition), which 
has values from 0 to 100 [1,8,9].
Data collection, statistical analysis
The independent variables were age, sex, level of 
education, marital status, increasing number of as-
sociated diseases, smoking abuse, religion, type of 
disease and time lapse from autologous PSCT. The 
dependent variables were EQ-5D score (dimen-
sions of QoL) and EQ-5D VAS (subjective health 
condition). The evaluation of questionnaires was 
carried out by means of descriptive analysis in ac-
cordance with the European Quality of Life Group 
Method (1,9). The effect of selected aspects of QoL 
of patients was evaluated by means of analysis of 
variance (ANOVA). StatSoft STATISTICA Base 7.1 
software was used for complete evaluation of data. 
The value p<0.05 was considered signiﬁ cant.
Procedure
The QoL questionnaire and a covering letter in 
which the whole project was explained, togeth-
er with a stamped envelope, were mailed to the 
respondent’s address. Completion of the ques-
tionnaire was voluntary and anonymous.
RESULTS
The above-mentioned aspects proved statistical-
ly signiﬁ cant dependence of QoL (EQ-5D score 
and EQ-5D VAS) on age in both cohorts (p<0.01) 
(Table 1 and Figure 1), religion in AML cohort 
(p<0.05) (Table 2), smoking abuse in both co-
horts (p<0.01) (Table 3 and Figure 2), level of 
education in AML cohort (p<0.05) (Table 4), in-
creasing number of associated diseases in AML 
cohort (p<0.05) (Table 5) and type of disease 
(p<0.05) (Table 6). The effect of other aspects of 
QoL was not proven as statistically signiﬁ cant.
The global QoL in patients with AML undergo-
ing autologous PSCT is at a much higher level 
(mean EQ-5D score was 75.1%, mean EQ-5D VAS 
was 67.5%) than in patients with MM undergo-
ing autologous PSCT (mean EQ-5D score 68.9%, 
mean EQ-5D VAS 66.6%).
DISCUSSION OF RESULTS
Five main outcomes follow from our study: 
1. The effect of age on QoL in AML and MM sur-
vivors undergoing autologous PSCT has been 
proved.
Our results show that a lower QoL correlates with 
increasing age of patients treated by means of au-
tologous PSCT. De Souza [10], Heinonen [11,12], 
Chiodi [13], Wang [14], Wong [15], Andrykowski 
[16] and Zittoun [17] discovered a similar trend 
in their studies. De Souza [14] points out in his 
longitudinal study conducted in a group of 26 
patients who underwent bone marrow trans-
plantation and peripheral stem cell transplanta-
tion lower QoL of these patients. De Souza [10] 
further explained his statements by the fact that 
with increasing age a number of associated dis-
eases can occur (polymorbidity). These diseases 
reduce QoL. Choidi [13] also agrees with this 
opinion in his cross-sectional study conducted 
in a group of 244 patients with haematological 
malignancies who underwent allogeneic BMT. 
Choidi [13] also points out the fact that in ad-
dition to polymorbidity a negative inﬂ uence of 
cGVHD on lower QoL in patients with increasing 
age should be stressed. Wang [14], Wong [15] 
and Andrykowski [16] also agree with the inﬂ u-
ence of cGVHD on lower QoL of patients with 
increasing age. Zittoun [17] discovered another 
interesting piece of information in his cross-sec-
tional study conducted in a group of 179 patients 
with haematological malignancies who under-
went HSCT. He [17] points out that increasing 
overall fatigue and emotional complaints which 
decrease QoL correlate with increasing age. So 
[18] also discovered an interesting piece of infor-
mation in his cross-sectional study conducted in 
a group of 157 patients with haematological ma-
lignancies who underwent BMT. He [18] proved 
a high degree of overall fatigue in patients over 
the age of 50 with associated diseases. Another 
author who agrees with Zittoun’s [17] and So’s 
[18] opinions is Saleh [19]. He [19] conducted 
a transversal study in a group of 41 patients who 
underwent BMT. This author points out that in 
patients with an increasing number of associated 
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Age range Numberof respondents
Mean EQ-5D
Score (in %)
Standard
deviation
Mean EQ-5D
VAS (in%)
Standard
deviation
20–29 1  70  0  60  0
30–39 1  98  0  95  0
40–49 5  86.2  15.7  73.6  13.9
50–59 3  60  14.5  58.3  2.4
60–69 2  61  15  56  4
Table 1. Comparison of mean EQ-5D score and EQ-5D VAS values in individual age groups in AML survivors (n=12, p<0.01).
Mean value
of EQ-5D score
and EQ-5D VAS
(in %)
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EQ-5D VAS
Age range (Number of respondents)
20−29 (0) 30−39 (0) 40−49 (2) 50−59 (13) 60−69 (13) 70−79 (4)
0
0
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Figure 1. Dependence of EQ-5D score and EQ-5D VAS on individual age groups in MM survivors (n=32, p<0.01).
Religion Numberof respondents
Mean EQ-5D
Score (in %)
Standard
deviation
Mean EQ-5D
VAS (in %)
Standard
deviation
Believers 8 83.9 15.9 71 16.6
Non-believers 4 57.5 17.6 60.5 10.2
Table 2. Comparison of mean EQ-5D score and EQ-5D VAS values with religion in AML survivors (n=12, p<0.05).
Smoking
abuse
Number
of respondents
Mean EQ-5D
Score (in %)
Standard
deviation
Mean EQ-5D
VAS (in %)
Standard
deviation
Non-smokers 6 90.7 11.4 77.2 16.4
Smokers 6 59.5 14.1 57.8 3.5
Table 3. Comparison of mean EQ-5D score and EQ-5D VAS values with smoking abuse in AML survivors (n=12, p<0.01).
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diseases there is a lower overall physical condi-
tion, and this means lower QoL [19].
2. The effect of religion on QoL in AML survivors 
undergoing autologous PSCT has been proved.
It is clear from our results that QoL in patients 
who underwent autologous PSCT and believed 
in God was higher than in patients who were 
non-believers. According to Pospisilova [20], 
real QoL is associated with spiritual growth of 
a human being. This means real inner wealth 
which nobody can give to or take from anoth-
er person. Creative values and values concern-
ing experience and attitudes are also impor-
tant. These values are according to Pospisilova 
[20] virtues in Christian tradition. Bach [21] re-
corded these changes in values in patients who 
Mean value
of EQ-5D score
and EQ-5D VAS
(in %)
EQ-5D score
EQ-5D VAS
Smoking abuse (Number of respondents)
Non-smokers (15) Former smokers (9) Smokers (8)
0
0
0
0
81.5
77.5
74
72
70
68
66
64
62
60
58
56
54
Figure 2. Dependence of EQ-5D score and EQ-5D VAS on smoking abuse in MM survivors (n=32, p<0.01).
Level of education Numberof respondents
Mean EQ-5D
Score (in %)
Standard
deviation
Mean EQ-5D
VAS (in %)
Standard
deviation
Elementary 2 43 4.2 53.5  2.12
Apprentice 3 67 8.5 60  0
Secondary 3 74 4.0 65  8.7
University 4 98 0 82  17.9
Table 4. Comparison of mean EQ-5D score and EQ-5D VAS values with level of education in AML survivors (n=12, p<0.05)).
Number of disease Numberof respondents
Mean EQ-5D
Score (in %)
Standard
deviation
Mean EQ-5D
VAS (in %)
Standard
deviation
0 3  88.7  16.2  71.7  20.2
1 4  83.2  18.7  77  15.7
2 4  64  16.6  58.8  2.5
3 and more 1  46  0  52  0
Table 5. Comparison of mean EQ-5D score and EQ-5D VAS values with increasing number of associated diseases in AML survivors (n=12, 
p<0.05).
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underwent BMT. The above-mentioned chang-
es often mean that the patient has to stop var-
ious activities, including his interests and hob-
bies [21]. Boyd [22] proved signiﬁ cant changes 
in patients who underwent HSCT and believed 
in God. Patients who believed in God had a high-
er QoL than non-believers [22].
3. The effect of smoking abuse on QoL in AML 
and MM survivors undergoing autologous PSCT 
has been proved.
In both cohorts of patients we proved lower QoL 
in smokers in comparison with non-smokers or 
former smokers. Chang [23] found an opposite 
trend in his longitudinal follow-up of patients 
with chronic myeloid leukaemia following all-
ogeneic HSCT, in whom the effect of alcohol 
and smoking abuse on quality of life was stud-
ied. The group consisted of 114 patients. The 
author did not prove in his study any effect of 
alcohol or smoking abuse on QoL in this group 
of patients [23].
4. The effect of level of education on QoL in AML 
survivors undergoing autologous PSCT has been 
proved.
Henoinen [11,12] points out in his longitudinal 
study conducted in a group of 109 patients who 
underwent allogeneic BMT a higher QoL in pa-
tients with secondary and university education. 
Andrykowski [16] arrived at a similar conclusion 
in his multicentre longitudinal study conducted 
in a group of 200 patients with haematoonco-
logical diseases who underwent BMT. He [16] 
proved a lower QoL in patients with lower ed-
ucation, meaning patients with elementary and 
apprentice education.
5. The effect of increasing number of associated 
diseases on QoL in AML survivors undergoing 
autologous PSCT has been proved.
Our results show that lower QoL correlates with 
increasing number of associated diseases. Our 
results agree with the results of signiﬁ cant stud-
ies conducted by De Souza [10] and Chiodi [13]. 
Zittoun [17] discovered an interesting piece of 
information which showed a correlation among 
increasing number of associated diseases, overall 
fatigue and emotional difﬁ culties. Another sci-
entist who agreed with this opinion was So [18] 
in his cross-sectional study conducted in a group 
of 157 patients with haematological malignancies 
Dimension of QoL Level of evaluation AML MM
Number of respondents  abs. rel  abs. rel.
Mobility no troubles  10 83.3%  13 41%
with troubles  2 16.7%  19 59%
immobile  0  0
Self-care no troubles  10 83.3%  26 81.2%
with troubles  2 16.7%  6 18.8%
incapable  0  0
Usual activities no troubles  9 75%  6 18.8%
with troubles  3 25%  26 81.2%
incapable  0  0
Pain/discomfort none  10 83.3%  9 28.1%
substantial  2 16.7%  22 68.8%
extreme  0  1 3.1%
Anxiety/depression none  9 75%  13 41%
substantial  2 16.6%  19 59%
extreme  1 8.4%  0
Number of respondents  12  32
Table 6. Comparison of AML and MM survivors according to the level of troubles and the type of disease (n=44, p<0.05).
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who underwent BMT. He [18] proved a high de-
gree of overall fatigue in patients over the age 
of 50 with associated diseases. Saleh [19] also 
agrees in his cross-sectional study conducted in 
a group of 41 patients who underwent BMT with 
Zittoun’s [17] and So’s [18] opinions. This au-
thor [19] stresses the fact that in patients with an 
increasing number of associated diseases there 
is lower overall physical ﬁ tness and this causes a 
lower QoL. Heinonen [11,12] recorded in his 
longitudinal study conducted in a group of 109 
patients who underwent allogeneic BMT a low-
er QoL in patients in connection with increasing 
number of associated diseases, increased morbid-
ity, increasing overall fatigue and worse quality of 
sleep. When he compared polymorbid men and 
women who underwent allogeneic BMT he dis-
covered a lower QoL in women [11,12].
CONCLUSIONS
It is common in clinical practice to evaluate a pa-
tient’s health condition and the success of the 
treatment based only on one type of markers, most 
often by means of somatic, laboratory or detect-
ing markers [1,2,25]. But the trend in modern 
medicine is to evaluate a patient’s health condi-
tion in a more complex way, using other aspects. 
QoL means a higher dimensional evaluation of a 
number of life aspects. Different aspects can be af-
fected in a different way in different phases of the 
disease and its treatment [1,2]. That is why this in-
formation enriches our knowledge concerning a 
patient’s needs, and it can signiﬁ cantly contribute 
to improvement in medical treatment. It can also 
help us to reveal the mechanisms which modify the 
origin and the course of disease [1,2,24–27].
We are aware of the fact that our study may be 
limited by a few factors: 1. The cross-sectional 
type of the study informs us only about the QoL 
in AML and MM survivors at a certain time un-
dergoing autologous PSCT and it does not show 
the developmental trend. 2. The study deals only 
with the inﬂ uence of selected aspects of QoL. 
We could add a few other factors. But we decid-
ed on these factors because patients were able 
and willing to provide this information in a ret-
rospectively and anonymously carried out study. 
3. The small group of AML survivors undergo-
ing autologous PSCT.
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